Pharvaris outlines 2025 strategic priorities

Berndt Modig, Chief Executive Officer of Pharvaris, said: “This year is paramount to Pharvaris as we continue clinical development of deucrictibant to help address unmet needs for those living with bradykinin- mediated angioedema. Pharvaris is committed to generating robust clinical data to build a compelling package supporting deucrictibant’s efficacy and safety profile. Our team is focused on the execution of two Phase 3 clinical studies in HAE, the expansion of our pipeline into AAE, and preparations for commercialization of deucrictibant pending regulatory submission and approval; we have significant resources in place to support these strategic investments and provide value for our shareholders.”

2025 strategic priorities

Long-term prophylaxis of HAE attacks

  • Initiated CHAPTER-3, a global pivotal Phase 3 study, evaluating deucrictibant for the prophylactic treatment of HAE attacks; topline data anticipated second half of
  • Prophylactic open-label extension study CHAPTER-4 on track to initiate in first quarter of 2

On-demand treatment of HAE attacks

  • Topline data from RAPIDe-3, a global Phase 3 study evaluating deucrictibant for the treatment of HAE attacks, anticipated first quarter 2026.
  • Phase 2/3 open-label extension, RAPIDe-2, of deucrictibant immediate-release capsule for the treatment of HAE attacks is ongoing. All participants from RAPIDe-2 Part A, as well as participants who have completed RAPIDe-3, have or will be offered to enter Part B, the open-label extension study of deucrictibant immediate-release capsule (20 mg), which is the dose being used in RAPIDe-3 and currently the intended commercial

Clinical development of deucrictibant in AAE-C1 INH

  • Clinical development plans of deucrictibant in acquired angioedema due to C1-INH deficiency (AAE-C1INH) underway. Pharvaris intends to initiate a clinical study in 2025 pending feedback from regulators.

Business updates

  • Expansion of Pharvaris team to support deucrictibant launch preparedness, as well as business growth and
  • HAE treatment experience and burden of disease data presented at recent medical Data from the Adelphi Disease Specific Programme, a real-world cross-sectional survey of physicians and people living with HAE, were presented at the Spanish Society of Allergology and Clinical Immunology (SEAIC) International Symposium and at the BSI Clinical Immunology Network (BSI-CIPN) Conference.

(Source: Pharvaris)